403 related articles for article (PubMed ID: 34818478)
21. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
Courtney KD; Infante JR; Lam ET; Figlin RA; Rini BI; Brugarolas J; Zojwalla NJ; Lowe AM; Wang K; Wallace EM; Josey JA; Choueiri TK
J Clin Oncol; 2018 Mar; 36(9):867-874. PubMed ID: 29257710
[TBL] [Abstract][Full Text] [Related]
22. First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma.
Dhawan A; Peereboom DM; Stevens GH
CNS Oncol; 2022 Jul; 11(3):CNS91. PubMed ID: 35819008
[TBL] [Abstract][Full Text] [Related]
23. Metastases to hemangioblastomas in von Hippel-Lindau disease.
Jarrell ST; Vortmeyer AO; Linehan WM; Oldfield EH; Lonser RR
J Neurosurg; 2006 Aug; 105(2):256-63. PubMed ID: 17219831
[TBL] [Abstract][Full Text] [Related]
24. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
[TBL] [Abstract][Full Text] [Related]
25. Metastatic renal cell carcinoma versus pancreatic neuroendocrine tumor in von Hippel-Lindau disease: treatment with interleukin-2.
Williams C; Walther M
ScientificWorldJournal; 2005 Jan; 5():9-10. PubMed ID: 15674444
[TBL] [Abstract][Full Text] [Related]
26. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
Kong HS; Lee S; Beebe K; Scroggins B; Gupta G; Lee MJ; Jung YJ; Trepel J; Neckers L
Mol Pharmacol; 2010 Dec; 78(6):1072-8. PubMed ID: 20813864
[TBL] [Abstract][Full Text] [Related]
27. Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report.
Taylor DG; Ilyas A; Mehta GU; Chen CJ; Schiff D; Oldfield EH; Asthagiri AR
J Clin Neurosci; 2018 Apr; 50():154-156. PubMed ID: 29396065
[TBL] [Abstract][Full Text] [Related]
28. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
29. Belzutifan-induced regression of retinal capillary hemangioblastoma: A case-series.
Ercanbrack CW; Elhusseiny AM; Sanders RN; Santos Horta E; Uwaydat SH
Am J Ophthalmol Case Rep; 2024 Mar; 33():102011. PubMed ID: 38374949
[TBL] [Abstract][Full Text] [Related]
30. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma.
Yu Y; Yu Q; Zhang X
Drug Discov Today; 2019 Dec; 24(12):2332-2340. PubMed ID: 31541711
[TBL] [Abstract][Full Text] [Related]
31. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance.
Louise M Binderup M; Smerdel M; Borgwadt L; Beck Nielsen SS; Madsen MG; Møller HU; Kiilgaard JF; Friis-Hansen L; Harbud V; Cortnum S; Owen H; Gimsing S; Friis Juhl HA; Munthe S; Geilswijk M; Rasmussen ÅK; Møldrup U; Graumann O; Donskov F; Grønbæk H; Stausbøl-Grøn B; Schaffalitzky de Muckadell O; Knigge U; Dam G; Wadt KA; Bøgeskov L; Bagi P; Lund L; Stochholm K; Ousager LB; Sunde L
Eur J Med Genet; 2022 Aug; 65(8):104538. PubMed ID: 35709961
[TBL] [Abstract][Full Text] [Related]
32. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of spinal cord hemangioblastoma in von Hippel-Lindau disease].
Nakashima H; Tokunaga K; Tamiya T; Matsumoto K; Ohmoto T; Furuta T
No Shinkei Geka; 1999 Jun; 27(6):533-40. PubMed ID: 10396736
[TBL] [Abstract][Full Text] [Related]
34. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
Tsimafeyeu I
J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
[TBL] [Abstract][Full Text] [Related]
35. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
[TBL] [Abstract][Full Text] [Related]
36. Targeting HIF-2 Alpha in Renal Cell Carcinoma.
Ahmed R; Ornstein MC
Curr Treat Options Oncol; 2023 Sep; 24(9):1183-1198. PubMed ID: 37403008
[TBL] [Abstract][Full Text] [Related]
37. Genetic study of a large Chinese kindred with von Hippel-Lindau disease.
Huang YR; Zhang J; Wang JD; Fan XD
Chin Med J (Engl); 2004 Apr; 117(4):552-7. PubMed ID: 15109448
[TBL] [Abstract][Full Text] [Related]
38. Neurologic manifestations of von Hippel-Lindau disease.
Butman JA; Linehan WM; Lonser RR
JAMA; 2008 Sep; 300(11):1334-42. PubMed ID: 18799446
[TBL] [Abstract][Full Text] [Related]
39. A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease.
Yuan G; Liu Q; Tong D; Liu G; Yi Y; Zhang J; Zhang Y; Wang LA; Wang L; Chen R; Guan Y; Yi X; Lan W; Jiang J
Cancer Biol Ther; 2018; 19(9):766-772. PubMed ID: 29947576
[TBL] [Abstract][Full Text] [Related]
40. A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas.
Heo SJ; Lee CK; Hahn KY; Kim G; Hur H; Choi SH; Han KS; Cho A; Jung M
Cancer Res Treat; 2016 Jan; 48(1):409-14. PubMed ID: 25715769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
